期刊文献+

New frontiers in proton therapy:applications in cancers 被引量:5

原文传递
导出
摘要 Proton therapy offers dominant advantages over photon therapy due to the unique depth-dose characteristics of proton,which can cause a dramatic reduction in normal tissue doses both distal and proximal to the tumor target volume.In turn,this feature may allow dose escalation to the tumor target volume while sparing the tumor-neighboring susceptible organs at risk,which has the potential to reduce treatment toxicity and improve local control rate,quality of life and survival.Some dosimetric studies in various cancers have demonstrated the advantages over photon therapy in dose distributions.Further,it has been observed that proton therapy confers to substantial clinical advantage over photon therapy in head and neck,breast,hepatocellular,and non-small cell lung cancers.As such,proton therapy is regarded as the standard modality of radiotherapy in many pediatric cancers from the technical point of view.However,due to the limited clinical evidence,there have been concerns about the high cost of proton therapy from an economic point of view.Considering the treatment expenses for late radiation-induced toxicities,cost-effective analysis in many studies have shown that proton therapy is the most cost-effective option for brain,head and neck and selected breast cancers.Additional studies are warranted to better unveil the cost-effective values of proton therapy and to develop newer ways for better protection of normal tissues.This review aims at reviewing the recent studies on proton therapy to explore its benefits and cost-effectiveness in cancers.We strongly believe that proton therapy will be a common radiotherapy modality for most types of solid cancers in the future.
出处 《Cancer Communications》 SCIE 2019年第1期557-563,共7页 癌症通讯(英文)
  • 相关文献

参考文献9

二级参考文献15

  • 1Miyatake S Kawabata S Kafimoto Y Aoki A Yokoyama K Yamada M Kuroiwa T Tsuji M Imahori Y Kirihata M Sakurai Y Masunaga S Nagata K Maruhashi A Ono K.Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages[J].中国神经肿瘤杂志,2005,3(4):266-266. 被引量:15
  • 2Wen-Yen Huang,Yee-Min Jen,Meei-Shyuan Lee,Li-Ping Chang,Chang-Ming Chen,Kai-Hsiung Ko,Kuen-Tze Lin,Jang-Chun Lin,Hsing-Lung Chao,Chun-Shu Lin,Yu-Fu Su,Chao-Yueh Fan,Yao-Wen Chang.Stereotactic Body Radiation Therapy in Recurrent Hepatocellular Carcinoma[J]. International Journal of Radiation Oncology, Biology, Physics . 2012 (2)
  • 3European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].Journal of Hepatology.2012(4)
  • 4Yohji Honda,Tomoki Kimura,Hiroshi Aikata,Tomoki Kobayashi,Takayuki Fukuhara,Keiichi Masaki,Takashi Nakahara,Noriaki Naeshiro,Atsushi Ono,Daisuke Miyaki,Yuko Nagaoki,Tomokazu Kawaoka,Shintaro Takaki,Akira Hiramatsu,Masaki Ishikawa,Hideaki Kakizawa,Masahiro Kenjo,Shoichi Takahashi,Kazuo Awai,Yasushi Nagata,Kazuaki Chayama.Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma[J].J Gastroenterol Hepatol.2013(3)
  • 5Wei Zhang,Jing Zhang,Wei Yan,Gan You,Zhaoshi Bao,Shouwei Li,Chunsheng Kang,Chuanlu Jiang,Yongping You,Yuxiang Zhang,Clark C. Chen,Sonya Wei Song,Tao Jiang.Whole‐genome microRNA expression profiling identifies a 5‐microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme[J].Cancer.2012(4)
  • 6Atsuya Takeda,Yohei Oku,Naoko Sanuki,Etsuo Kunieda,Naoyoshi Koike,Yousuke Aoki,Toshio Ohashi,Shogo Iwabuchi,Kentaro Takatsuka,Toshiaki Takeda,Akitomo Sugawara.Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma[J].Radiotherapy and Oncology.2011(3)
  • 7Rafael A. Ibarra,Daniel Rojas,Laura Snyder,Min Yao,Jeffrey Fabien,Michael Milano,Alan Katz,Karyn Goodman,Kevin Stephans,Galal El-Gazzaz,Federico Aucejo,Charles Miller,John Fung,Simon Lo,Mitchell Machtay,Juan R. Sanabria.Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors[J].Acta Oncologica.2012(5)
  • 8Takahisa Eriguchi,Atsuya Takeda,Naoko Sanuki,Yohei Oku,Yousuke Aoki,Naoyuki Shigematsu,Etsuo Kunieda.Acceptable Toxicity After Stereotactic Body Radiation Therapy for Liver Tumors Adjacent to the Central Biliary System[J].International Journal of Radiation Oncology Biology Physics.2012
  • 9Alan W. Katz,Sheema Chawla,Zhenhong Qu,Randeep Kashyap,Michael T. Milano,Aram F. Hezel.Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation[J].International Journal of Radiation Oncology Biology Physics.2012(3)
  • 10Jin‐Kyu Kang,Mi‐Sook Kim,Chul Koo Cho,Kwang Mo Yang,Hyung Jun Yoo,Jin Ho Kim,Sun Hyun Bae,Da Hoon Jung,Kum Bae Kim,,Dong Han Lee,Chul Ju Han,Jin Kim,Su Cheol Park,Young Han Kim.Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization[J].Cancer.2012(21)

共引文献63

同被引文献23

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部